Table 2 Risks of NTM and MTB measured by sex, age, and Charlson index score for matched cohorts.

From: TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area

Variable

TNFI untreated RA group (N = 4356/ 31,863 PY)

TNFI treated RA group (N = 1089/ 7920 PY)

Compared to TNFI untreated RA group

Event

PY

Rate#

Event

PY

Rate#

IRR* (95% CI)

Adjusted HR† (95% CI)

MTB

80

31,863

251.1

27

7920

340.9

1.358 (0.844–2.124)

1.352 (0.874–2.091)

NTM

60

32,011

187.4

26

7925

328.1

1.750 (1.060–2.817)**

1.751 (1.105–2.774)**

Gender

 Male

14

5089

275.1

2

1290

155.0

0.563 (0.062–2.453)

0.570 (0.129–2.510)

 Female

46

26,921

170.9

24

6635

361.7

2.117 (1.236–3.541)**

2.108 (1.287–3.453)**

Age

 18 ≤ age < 50

12

12,199

9.84

6

3039

19.74

2.007 (0.618–5.776)

1.997 (0.749–5.326)

 50 ≤ age < 65

28

13,997

20.00

14

3451

40.57

2.028 (0.987–3.983)

2.018 (1.062–3.833)**

 65 ≤ age

20

5816

34.39

6

1435

41.82

1.216 (0.400–3.139)

1.199 (0.481–2.987)

CCI

 0

45

24,837

181.2

19

5999

316.7

1.748 (0.966–3.05)

1.742 (1.019–2.978)**

 ≥ 1

15

7174

209.1

7

1926

363.4

1.738 (0.600–4.529)

1.766 (0.720–4.334)

  1. Rate#, incidence rate, per 100,000 person-years; IRR*, incidence rate ratio; Adjusted HR†; model manual adjusted for sex, age, and CCI score; **p < 0.001.
  2. CCI Charlson comorbidity index, CI confidence interval, HR hazard ratio, MTB mycobacterium tuberculosis, NTM nontuberculosis mycobacterium, PY person-year, RA rheumatoid arthritis, TB tuberculosis, TNFI tumor necrosis factor inhibitor.
Back to article page